Rare coding variants and breast cancer risk: Evaluation of susceptibility loci identified in genome-wide association studies

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 4, 2014, Pages 622-628

  Zhang, Yanfeng ^a   Long, Jirong ^a   Lu, Wei ^c   Shu, Xiao Ou ^a   Cai, Qiuyin ^a   Zheng, Ying ^c   Li, Chun ^b   Li, Bingshan ^a   Gao, Yu Tang ^c   Zheng, Wei ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHANGHAI CANCER INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; EDEM 1 PROTEIN; EFEMP 2 PROTEIN; FBXO 18 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MISSENSE MUTATION;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84898735984     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-1043     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Cariaso M, Lennon G. SNPedia: a Wiki supporting personal genome annotation, interpretation and analysis. Nucleic Acids Res 2012;40:D1308-D1312.
3. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013;45:353-61.
4. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491:56-65.
5. Bonnefond A, Clement N, Fawcett K, Yengo L, Vaillant E, Guillaume JL, et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 2012;44:297-301.
6. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009;324:387-9.
7. Johansen CT, Wang J, Lanktree MB, Cao H, McIntyre AD, Ban MR, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010;42:684-7.
8. McInerney NM, Miller N, Rowan A, Colleran G, Barclay E, Curran C, et al. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat 2010;121:203-10.
9. Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, et al. MosaicPPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 2013;493:406-10.
10. Lu W, Wang X, Lin H, Lindor N, Couch F. Mutation screening of RAD51C in high-risk breast and ovarian cancer families. Familial Cancer 2012;11:381-5.
11. Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009;85:427-46.
12. Le Calvez-Kelm F, Lesueur F, Damiola F, Vallee M, Voegele C, Babikyan D, et al. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res 2011;13:R6.
13. Dowty J, Lose F, Jenkins M, Chang JH, Chen X, Beesley J, et al. The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian women. Breast Cancer Res Treat 2008;112:35-9.
14. Gao YT, Shu XO, Dai Q, Potter JD, Brinton LA, Wen W, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai breast cancer study. Int J Cancer 2000;87:295-300. (Pubitemid 30434361)
15. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009;41:324-8.
16. Long J, Cai Q, Sung H, Shi J, Zhang B, Choi JY, et al. Genome-wide association study in East Asians identifies novel susceptibility loci for breast cancer. PLoS Genet 2012;8:e1002532.
17. Exomechip design [Internet]. Michigan: University of Michigan; 2013 [cited 2013 Mar 19]. Available from: http://genome.sph.umich.edu/wiki/Exome- Chip-Design.
18. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75. (Pubitemid 47330214)
19. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-9. (Pubitemid 44141658)
20. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
21. EPACTS [Internet]. Michigan: University of Michigan; 2013 [cited 2013 Mar 19]. Available from: http://genome.sph.umich.edu/wiki/EPACTS.
22. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al. Optimal uni fied approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am J Hum Genet 2012;91:224-37.
23. Wu M, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet 2011;89:82-93.
24. Exome Variant Server [Internet]. Washington: University of Washington; 2013 [cited 2013 Jul 11]. Available from: http://evs.gs.washington.edu/EVS.
25. Breast Cancer Information Core [Internet]. Bethesda: National Institutes of Health; 2013 [cited 2013 Aug 18]. Available from: http://research.nhgri.nih. gov/bic/.
26. MacArthur DG, Balasubramanian S, Frankish A, Huang N, Morris J, Walter K, et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science 2012;335:823-8.
27. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012;337:64-9.
28. Dasouki M, Markova D, Garola R, Sasaki T, Charbonneau NL, Sakai LY, et al. Compound heterozygous mutations in fibulin-4 causing neonatal lethal pulmonary artery occlusion, aortic aneurysm, arachnodactyly, and mild cutis laxa. Am J Med Genet 2007;143A:2635-41. (Pubitemid 350076765)
29. Yao L, Lao W, Zhang Y, Tang X, Hu X, He C, et al. Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues. J Proteome Res 2012;11:3281-94.
30. Colas E, Perez C, Cabrera S, Pedrola N, Monge M, Castellvi J, et al. Molecular markers of endometrial carcinoma detected in uterine aspirates. Int J Cancer 2011;129:2435-44.
31. Yuen HF, McCrudden CM, Huang YH, Tham JM, Zhang X, Zeng Q, et al. TAZ expression as a prognostic indicator in colorectal cancer. PLoS ONE 2013;8:e54211.
32. Vogt J, Agrawal S, Ibrahim Z, Southwood TR, Philip S, MacPherson L, et al. Striking intrafamilial phenotypic variability in Aicardi-Goutieres syndrome associated with the recurrent Asian founder mutation in RNASEH2C. Am J Med Genet 2013;161:338-42.
33. Rice G, Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007;81:713-25. (Pubitemid 47596540)
34. Reijns MAM, Bubeck D, Gibson LCD, Graham SC, Baillie GS, Jones EY, et al. The structure of the human rnase h2 complex defines key interaction interfaces relevant to enzyme function and human disease. J Biol Chem 2011;286:10530-9.
35. Kim J-H, Kim J, Kim D-H, Ryu G-H, Bae S-H, Seo Y-S. SCFhFBH1 can act as helicase and E3 ubiquitin ligase. Nucleic Acids Res 2004;32:2287-97. (Pubitemid 38854783)
36. Kim J, Kim JH, Lee SH, Kim DH, Kang HY, Bae SH, et al. The novel human DNA helicase hFBH1 Is an F-box protein. J Biol Chem 2002;277:24530-7. (Pubitemid 34951979)
37. Jeong YT, Rossi M, Cermak L, Saraf A, Florens L, Washburn MP, et al. FBH1 promotes DNA double-strand breakage and apoptosis in response to DNA replication stress. J Cell Biol 2013;200:141-9.
38. Benson JR. Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol 2004;5:229-39. (Pubitemid 38391218)
39. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005;23:2078-93.
40. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-20. (Pubitemid 43980540)
41. Ma X, Beeghly-Fadiel A, Lu W, Shi J, Xiang YB, Cai Q, et al. Pathway analyses identify TGFBR2 as potential breast cancer susceptibility gene: results from a consortium study among Asians. Cancer Epidemiol Biomarkers Prev. 2012;21:1176-84.